Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 1.00 |
| ▸ | POLB | P06746 | 9/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.78 |
| ▸ | MEN1 | O00255 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.78 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.71 |
| ▸ | PPARG | P37231 | 1/20 | 0.71 |
| ▸ | GFER | P55789 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29703130 | 1.00 | KDM4E (1.00) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4472928 | 0.99 | KDM4E (0.97) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL4460070 | 0.89 | KDM4E (0.80) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL28520534 | 0.89 | KDM4E (0.80) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL13312200 | 0.89 | KDM4E (0.80) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL12488937 | 0.83 | KDM4E (1.00) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL13912480 | 0.83 | KDM4E (0.73) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL12524825 | 0.83 | KDM4E (0.73) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL18746 | 0.82 | KDM4E (0.83) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL29359819 | 0.82 | KDM4E (0.83) | KDM4EPOLBTDP1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | claimed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | claimed |
| EP-4275759-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250074880-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2025-03-06 | — | — | US | disclosed |
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12129248-B2 | Chromobox protein inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4337640-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | Istituto Europeo di Oncologia S.r.l. (IT) | 2024-03-20 | — | — | EP | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4275759-A2 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | Dana-Farber Cancer Institute, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3515449-B1 | QUINOLINE DERIVATIVES AS CHROMOBOX (CBX) PROTEIN INHIBITORS FOR TREATING CANCER | DANA FARBER CANCER INST INC (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-1276211-A | Use of non-peptides NK3-antagonist | SMITHKINE BEECHEM S P A (IT) | 2000-12-13 | — | — | CN | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0940391-A2 | Quinoline derivatives as tachykinin NK3 receptor antagonists | Smithkline Beecham Farmaceutici S.p.A. (IT) | 1999-09-08 | — | — | EP | disclosed |
| EP-0874827-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | Smithkline Becham S.P.A. (IT) | 1998-11-04 | — | — | EP | disclosed |
| US-5811553-A | TREATMENT OF NEURODEGENERATIVE DISORDERS, PULMONARY DISORDERS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1998-09-22 | — | — | US | disclosed |
| EP-0804419-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1997-11-05 | — | — | EP | disclosed |
| CN-1156451-A | Use as tachykinin NK3Quinoline derivatives of receptor antagonists | SMITHKLINE BEECHAM FARMA (IT) | 1997-08-06 | — | — | CN | disclosed |
| WO-1997019927-A1 | QUINOLINE DERIVATIVES AS NK3 ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 1997-06-05 | — | — | WO | disclosed |
| WO-1995032948-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM FARMACEUTICI S.P.A. (IT) | 1995-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074880-A1 | NOVEL QUINOLINE DERIVATIVES AND USES THEREOF | NDC1, CHD1L, NUMA1 | KDM4E 951/4885POLB 637/4885TDP1 603/4885 |
| US-20250034126-A1 | CHROMOBOX PROTEIN INHIBITORS AND USES THEREOF | CBX2, CBX3, CBX6 | KDM4E 528/4885POLB 3744/4885TDP1 2050/4885 |
| US-12129248-B2 | Chromobox protein inhibitors and uses thereof | CBX2, CBX3, CBX6 | KDM4E 528/4885POLB 3744/4885TDP1 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.